Comparison of a new rapid method for the determination of adalimumab serum levels with two established ELISA kits

2019 ◽  
Vol 57 (12) ◽  
pp. 1906-1914 ◽  
Author(s):  
Emilio J. Laserna-Mendieta ◽  
Sara Salvador-Martín ◽  
Laura Arias-González ◽  
Miriam Ruiz-Ponce ◽  
Luis A. Menchén ◽  
...  
Keyword(s):  
Rapid Method ◽  
Repeated Measures ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Therapeutic Drug ◽  
High Agreement ◽  
Deming Regression ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Abstract Background Therapeutic drug monitoring (TDM) of adalimumab (ADA) in inflammatory bowel diseases (IBDs) has gained increased attention since several studies showed a correlation between drug levels and mucosal healing. The limitations of routine usage of enzyme-linked immunoabsorbent assay (ELISA) kits for measuring serum ADA concentrations have prompted the development of rapid methods, such as Quantum Blue (QB). We evaluated the interchangeability and agreement between the QB method and two established ELISA kits, Promonitor (PM) and Lisa-Tracker (LT). Methods Fifty samples from patients with IBD were included. Quantitative analysis was performed using the ANOVA test for repeated measures, Deming regression and the Bland-Altman plot. Clinical implications were evaluated by concordance in classifying patients into therapeutic windows according to the proposed cut-off levels for subtherapeutic (either <5 or <7.5 μg/mL) and supratherapeutic (>12 μg/mL) ranges. Results Statistical differences were detected between the QB method and the two ELISA kits, with QB overestimating ADA serum values compared to them. A lack of interchangeability was observed between methods, with greater differences as ADA levels increased. An analysis of a sub-set of samples with ADA values below 9 μg/mL (n = 25) showed that QB fulfilled the criteria to be interchangeable with the LT assay. Concordance for patient classification into ADA therapeutic windows was better for QB vs. LT than for QB vs. PM, with high agreement (>75%) for subtherapeutic levels among the three methods. Conclusions Although quantitative differences existed between the rapid method and ELISA kits that hampered their interchangeability, the agreement for identifying patients with subtherapeutic values of ADA was high.

scholarly journals New steps in infliximab therapeutic drug monitoring in patients with inflammatory bowel diseases

2019 ◽  
Vol 85 (4) ◽  
pp. 722-728 ◽  
Author(s):  
Benjamin Nemoz ◽  
David Ternant ◽  
Sébastien Bailly ◽  
Elodie Gautier‐Veyret ◽  
Jean‐François Jourdil ◽  
...  
Keyword(s):  
Therapeutic Drug Monitoring ◽  
Inflammatory Bowel Diseases ◽  
Drug Monitoring ◽  
Therapeutic Drug ◽  
Bowel Diseases ◽  
Inflammatory Bowel

Vedolizumab for the treatment of inflammatory bowel diseases: from symptomatic control to mucosal healing

Immunotherapy ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 565-575
Author(s):  
Ferdinando D’Amico ◽  
Gionata Fiorino ◽  
Laurent Peyrin-Biroulet ◽  
Silvio Danese
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Mucosal Healing ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Symptomatic Control

scholarly journals P186 Association between anti-TNF serum levels and mucosal healing in inflammatory bowel disease

2017 ◽  
Vol 11 (suppl_1) ◽  
pp. S171-S171
Author(s):  
M. Chaparro ◽  
M. Barreiro-de Acosta ◽  
A. Echarri ◽  
R. Almendros ◽  
J. Barrio ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Serum Levels ◽  
Mucosal Healing ◽  
Inflammatory Bowel

scholarly journals Magnification endoscopy with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with inflammatory bowel disease

2019 ◽  
Vol 07 (08) ◽  
pp. E1018-E1026 ◽  
Author(s):  
Entcho Klenske ◽  
Raja Atreya ◽  
Arndt Hartmann ◽  
Sarah Fischer ◽  
Simon Hirschmann ◽  
...  
Keyword(s):  
Strong Correlation ◽  
Interobserver Agreement ◽  
Intestinal Inflammation ◽  
Mucosal Healing ◽  
High Accuracy ◽  
Magnification Endoscopy ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Established Treatment ◽  
Microscopic Inflammation

Abstract Background and study aims Apart from mucosal healing as an established treatment goal in inflammatory bowel diseases (IBD), recent evidence suggests that histologic healing may become another key prognostic parameter in IBD patients. We aimed to evaluate whether magnification endoscopy with optical chromoendoscopy can accurately assess histologic inflammation in IBD patients. Patients and methods In this prospective study, 82 patients with IBD (30 UC, 52 CD) were included. In all patients, magnification endoscopy in conjunction with optical chromoendoscopy was performed and rated on a novel magnification endoscopy score by three independent endoscopists. Targeted biopsies of the imaged areas were obtained and results were compared against two histological scores in UC (Robarts Histopathology Index, RHI; Nancy Histology Index, NHI) and one score in CD (modified Riley index, mRI). Moreover, interobserver agreement was calculated. Results Magnification endoscopy showed strong correlation with histopathologic scoring in both UC (RHI: r = 0.83, NHI: r = 0.78, P < 0.05) and CD (mRI: r = 0.74, P < 0.05) with high accuracy, sensitivity, and specificity. Further, 25 % of patients with mucosal healing on standard endoscopy showed signs of microinflammation on magnification endoscopy with optical chromoendoscopy, while none of the patients with mucosal and vascular healing under magnification endoscopy with optical chromoendoscopy exhibited microscopic inflammation. Interobserver agreement for grading intestinal inflammation by magnification endoscopy with optical chromoendoscopy was substantial (κ > 0.7). Conclusion Magnification endoscopy in combination with optical chromoendoscopy shows strong correlation with histologic inflammation in patients with IBD. This approach has potential to reduce physical biopsies for monitoring of inflammatory activity in patients with IBD during colonoscopy.

scholarly journals Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing

2020 ◽  
Vol 26 (8) ◽  
pp. 1131-1143 ◽  
Author(s):  
Gwo-tzer Ho ◽  
Jennifer A Cartwright ◽  
Emily J Thompson ◽  
Calum C Bain ◽  
Adriano G Rossi
Keyword(s):  
Inflammatory Bowel Diseases ◽  
Inflammatory Cell ◽  
Mucosal Healing ◽  
Treatment Target ◽  
Resolution Of Inflammation ◽  
Epithelial Repair ◽  
New Knowledge ◽  
Bowel Diseases ◽  
Inflammatory Bowel ◽  
Macrophage Populations

Abstract Despite significant recent therapeutic advances, complete mucosal healing remains a difficult treatment target for many patients with inflammatory bowel diseases (IBD) to achieve. Our review focuses on the translational concept of promoting resolution of inflammation and repair as a necessary adjunctive step to reach this goal. We explore the roles of inflammatory cell apoptosis and efferocytosis to promote resolution, the new knowledge of gut monocyte-macrophage populations and their secreted prorepair mediators, and the processes of gut epithelial repair and regeneration to bridge this gap. We discuss the need and rationale for this vision and the tangible steps toward integrating proresolution therapies in IBD.

Sign in / Sign up

Export Citation Format

Share Document